Contributions to Science

• The Lancet Infectious Diseases (1*Aruhomukama D. “Antimicrobial resistance data, frugal sequencing and low-income countries in Africa.” The Lancet Infectious Diseases. https://pubmed.ncbi.nlm.nih.gov/35594898/ )

(ii) 1*Aruhomukama D. “Extending political will into action in African LMICs: abating global antimicrobial resistance.” The Lancet Microbe. https://pubmed.ncbi.nlm.nih.gov/35544090/ 

(iii) *Aruhomukama D. “The need to improve antimicrobial susceptibility testing capacity in Ugandan health facilities: insights from a surveillance primer.” Antimicrobial Resistance and Infection Control. https://pubmed.ncbi.nlm.nih.gov/35115045/ 

(iv) 2Aruhomukama D. “Antibiotic-resistance in medically important bacteria isolated from commercial herbal medicines in Africa from 2000 to 2021: a systematic review and meta-analysis.” Antimicrobial Resistance and Infection Control. https://pubmed.ncbi.nlm.nih.gov/35063036/ 

(v) *Aruhomukama D. “Transmission Dynamics of Antimicrobial Resistance at a National Referral Hospital in Uganda.” American Journal of Tropical Medicine and Hygiene. https://pubmed.ncbi.nlm.nih.gov/34181567/ 

(vi) 2Aruhomukama D. “Gastrointestinal Tract Colonization Rate of Extended-Spectrum Beta-Lactamase-Producing Gram-Negative Bacteria and Associated Factors Among Orthopaedic Patients in a Tertiary Hospital in Tanzania: Implications for Infection Prevention.” Infection and Drug Resistance. https://pubmed.ncbi.nlm.nih.gov/34007192/ 

(vii) 2Aruhomukama D. “Increasing Antimicrobial Resistance in Surgical Wards at Mulago National Referral Hospital, Uganda, from 2014 to 2018-Cause for Concern?” Tropical Medicine and Infectious Disease. https://pubmed.ncbi.nlm.nih.gov/34069345/ 

(viii) 2Aruhomukama D. “Genomics and bioinformatics capacity in Africa: no continent is left behind.” Genome. https://pubmed.ncbi.nlm.nih.gov/33433259/ 

(ix) *Aruhomukama D. “Efficacy of Face Masks Used in Uganda: A Laboratory-Based Inquiry during the COVID-19 Pandemic.” American Journal of Tropical Medicine and Hygiene. https://pubmed.ncbi.nlm.nih.gov/33724922/ 

(x) 1*Aruhomukama D. “Publishing research-demystifying the course.” PAMJ-One-Health. https://www.one-health.panafrican-med-journal.com/content/article/4/2/full/ 

(xi) *Aruhomukama D. “Face-Masking, an Acceptable Protective Measure against COVID-19 in Ugandan High-Risk Groups.” American Journal of Tropical Medicine and Hygiene. https://pubmed.ncbi.nlm.nih.gov/33319741/ 

(xii) 1*Aruhomukama D. “Review of phenotypic assays for detection of extended-spectrum β-lactamases and carbapenemases: a microbiology laboratory bench guide.” African Health Sciences. https://pubmed.ncbi.nlm.nih.gov/33402954/ 

(xiii) *Aruhomukama D. “Whole-genome sequence analysis reveals evolution of antimicrobial resistance in a Ugandan colistin-resistant Acinetobacter baumannii.” bioRxiv. https://www.biorxiv.org/content/10.1101/2020.06.18.159236v1.abstract 

(xiv) 3Aruhomukama D. “High Prevalence of Antibiotic-Resistant Escherichia coli Serotype O157: H7 among Pastoral Communities in Rural Uganda.” Microbiology Research Journal International. https://journalmrji.com/index.php/MRJI/article/view/30230 

(xv) 1*Aruhomukama D. “blaVIM- and blaOXA-mediated carbapenem resistance among Acinetobacter baumannii and Pseudomonas aeruginosa isolates from the Mulago hospital intensive care unit in Kampala, Uganda.” BMC Infectious Diseases. https://pubmed.ncbi.nlm.nih.gov/31619192/ 

(xvi) 1*Aruhomukama D. “Investigating colistin drug resistance: The role of high-throughput sequencing and bioinformatics.” F1000Research. https://pubmed.ncbi.nlm.nih.gov/31354944/